COVID-19ワクチン市場：技術、用途、地域別、2026～2032年

COVID-19ワクチン市場評価-2026-2032

COVID-19ワクチン接種の需要増につながる、ワクチンの利点に対する社会的理解の高まり世界中でワクチン接種を促進するための政府や組織からの資金提供や支援が増加し、市場規模は2024年に76億4,000万米ドルを超え、2032年には約126億4,000万米ドルに達する見込みです。

これに加えて、生産効率と流通を向上させるワクチン開発と送達方法の革新が、COVID-19ワクチンの採用に拍車をかけています。製薬会社、政府、NGO間のパートナーシップにより、研究と流通への取り組みが加速し、2026年から2032年までのCAGRは7.16%で市場は成長します。

COVID-19ワクチン市場：定義/概要

COVID-19ワクチンは、COVID-19の原因となるSARS-CoV-2ウイルスに対する免疫を獲得するために設計された生物学的製剤です。これらのワクチンは、スパイクタンパク質やmRNAといったウイルスの無害な成分を体内に導入することで機能します。これにより、将来ウイルスにさらされた場合に免疫系がウイルスを認識して反応するようになり、重症化や感染の予防に役立ちます。

COVID-19ワクチンの応用は、パンデミックの制圧に極めて重要でした。ワクチン接種キャンペーンは、集団における広範な免疫の獲得を目指し、ウイルスに関連した入院率や死亡率を大幅に減少させました。個人の予防に加え、広範なワクチン接種は集団免疫に貢献し、ウイルスの蔓延を抑え、正常な社会機能への復帰を促進するのに役立っています。

小児ワクチン接種への関心の高まりは、COVID-19ワクチンの採用をどのように増加させるか？

世界のワクチン接種率の上昇がCOVID-19ワクチン市場を前進させており、世界各国の政府が包括的な予防接種プログラムを実施しています。WHOによると、2023年12月現在、COVID-19ワクチンは全世界で135億回接種されており、大規模な市場浸透を示しています。新たな変異型の出現により、最新の製剤に対する需要が引き続き高まっている一方、保健機関は脆弱な集団に対するブースター用量の重要性を強調しています。

ワクチンプラットフォームの技術的進歩は、特にmRNA技術を通じて、市場の状況を一変させました。米国CDCは、2020～2021年の初期試験において、mRNAワクチンが重症COVID-19症例の予防に90%以上の有効性を示したと報告しました。2023年9月、ファイザーとModernaは、より新しいOmicron亜種をターゲットとした最新の一価XBB.1.5ワクチンを発売し、市場でのプレゼンスを拡大しました。

小児用ワクチンや免疫不全患者用の特殊製剤への注目の高まりは、新たな市場機会を生み出しています。欧州医薬品庁（EMA）のデータによると、2023年半ばまでにEU/EEAの12～17歳の小児の約82％がCOVID-19ワクチンを少なくとも1回接種しています。最近では、ノババックスが2024年3月にCOVID-19-インフルエンザ混合ワクチンの臨床試験に成功したと発表しており、季節性ワクチン接種のアプローチに革命をもたらし、市場の可能性を拡大する可能性があります。

COVID-19ワクチン市場の成長を妨げるサプライチェーンの混乱とは？

COVID-19ワクチン市場は、その成長とアクセシビリティに影響を与えうるいくつかの抑制要因に直面しています。主な制約の1つはワクチン接種のためらいで、誤った情報、副作用への恐怖、製薬会社に対する不信感などが原因で、個人がワクチン接種を嫌がったり拒否したりすることがあります。このような躊躇はワクチン接種率の低下につながり、公衆衛生の努力を損ない、パンデミックを長引かせる。

サプライチェーンの混乱もCOVID-19ワクチン市場に大きな課題をもたらしています。ワクチンの急速な開発と展開は、製造と流通のネットワークに多大な圧力をかけています。原材料の不足、輸送の問題、物流の課題といった要因は、特に中低所得国においてワクチンの入手の遅れにつながる可能性があります。

ワクチン開発者は各国の複雑な承認プロセスを通過しなければならないため、規制上のハードルも足かせとなります。規制基準の違いは新ワクチンの導入を遅らせ、市場拡大を制限する可能性があります。さらに、ワクチンの安全性と有効性を監視するためには、継続的なサーベイランスと市販後調査が必要であり、これが承認プロセスをさらに複雑にしています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 COVID-19ワクチン市場：技術別

• mRNAワクチン
• ウイルスベクターワクチン
• DNAワクチン
• タンパク質サブユニットワクチン
• 不活化ワクチン

第5章 COVID-19ワクチン市場：用途別

• 一次接種
• 追加接種

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Pfizer
• Moderna
• AstraZeneca
• Johnson & Johnson
• Sinopharm
• Sinovac Biotech
• Bharat Biotech

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Covid-19 Vaccine Market Valuation - 2026-2032

Growing public understanding of vaccine benefits, leading to higher demand for COVID-19 vaccinations. Increased funding and support from governments and organizations to promote vaccination efforts worldwide is driving the market size surpass USD 7.64 Billion valued in 2024 to reach a valuation of around USD 12.64 Billion by 2032.

In addition to this, innovations in vaccine development and delivery methods enhancing production efficiency and distribution is spurring up the adoption of Covid-19 vaccine. Partnerships between pharmaceutical companies, governments, and NGOs accelerating research and distribution efforts is enabling the market to grow at a CAGR of 7.16% from 2026 to 2032.

Covid-19 Vaccine Market: Definition/ Overview

A COVID-19 vaccine is a biological preparation designed to provide immunity against the SARS-CoV-2 virus, which causes COVID-19. These vaccines work by introducing a harmless component of the virus, such as a spike protein or mRNA, into the body. This triggers the immune system to recognize and respond to the virus if exposed in the future, helping to prevent severe illness and transmission.

The application of COVID-19 vaccines has been crucial in controlling the pandemic. Vaccination campaigns have aimed to achieve widespread immunity in populations, significantly reducing hospitalization rates and deaths associated with the virus. In addition to individual protection, widespread vaccination contributes to herd immunity, helping to limit the virus's spread and facilitating the return to normal societal functions.

How will Growing Focus on Pediatric Vaccinations Increase Adoption of Covid-19 Vaccine?

Rising global vaccination rates have propelled the Covid-19 vaccine market forward, with governments worldwide implementing comprehensive immunization programs. According to the WHO, as of December 2023, over 13.5 billion Covid-19 vaccine doses had been administered globally, demonstrating massive market penetration. The emergence of new variants continues to drive demand for updated formulations, while health organizations emphasize the importance of booster doses for vulnerable populations.

Technological advancements in vaccine platforms have revolutionized the market landscape, particularly through mRNA technology. The US CDC reported that mRNA vaccines showed over 90% efficacy in preventing severe Covid-19 cases during initial trials in 2020-2021. In September 2023, Pfizer and Moderna launched their updated monovalent XBB.1.5 vaccines, targeting newer Omicron subvariants and expanding their market presence.

Growing focus on pediatric vaccinations and specialized formulations for immunocompromised individuals has created new market opportunities. The European Medicines Agency (EMA) data showed that approximately 82% of children aged 12-17 in the EU/EEA received at least one Covid-19 vaccine dose by mid-2023. Recently, Novavax announced successful trials of its combination Covid-19-influenza vaccine in March 2024, potentially revolutionizing the seasonal vaccination approach and expanding market possibilities.

How Supply Chain Disruptions Hampering Covid-19 Vaccine Market Growth?

The COVID-19 vaccine market faces several restraints that can impact its growth and accessibility. One major constraint is vaccine hesitancy, where individuals may be reluctant or refuse to receive the vaccine due to misinformation, fear of side effects, or distrust in pharmaceutical companies. This hesitancy can lead to lower vaccination rates, undermining public health efforts and prolonging the pandemic.

Supply chain disruptions have also posed significant challenges to the COVID-19 vaccine market. The rapid development and deployment of vaccines put immense pressure on manufacturing and distribution networks. Factors such as shortages of raw materials, transportation issues, and logistical challenges can lead to delays in vaccine availability, particularly in low- and middle-income countries.

Regulatory hurdles represent another restraint, as vaccine developers must navigate complex approval processes in various countries. Differences in regulatory standards can slow down the introduction of new vaccines and limit market expansion. Additionally, ongoing surveillance and post-marketing studies are necessary to monitor vaccine safety and efficacy, which can further complicate the approval process.

Category-Wise Acumens

Will Rise in Adoption of mRNA Technology Drive Covid-19 Vaccine Market Growth?

mRNA technology is expected to dominate Covid-19 vaccine market. The revolutionary mRNA technology is emerging as a game-changer in the Covid-19 vaccine landscape, offering unprecedented speed in vaccine development and manufacturing. According to the US FDA, mRNA vaccines demonstrated remarkable efficacy rates of 94-95% in preventing symptomatic Covid-19 infections during initial clinical trials in 2020. Moderna and Pfizer-BioNTech's success with mRNA platforms has sparked increased investment in this technology, with both companies announcing expanded research facilities and enhanced production capabilities throughout 2023 to meet global demand.

The adaptability of mRNA technology has proven crucial in responding to emerging variants, enabling rapid modification of vaccine formulations. The European Medicines Agency reported that over 600 million mRNA vaccine doses were administered in the EU/EEA by December 2023, establishing them as the predominant vaccine type. In February 2024, Moderna announced positive results from its next-generation mRNA platform trials, promising enhanced stability at regular refrigeration temperatures and potentially eliminating the ultra-cold storage requirement that initially challenged distribution.

Will Rise in Adoption of Booster Dose Drive Covid-19 Vaccine Market Growth?

Booster dose is anticipated to hold major share in the Covid-19 vaccine market. The increasing emphasis on booster doses has become a significant driver in the Covid-19 vaccine market, as health authorities worldwide recommend additional shots to maintain immunity levels. The US CDC reported that by January 2024, over 56.5% of eligible adults had received at least one booster dose, highlighting substantial market potential. Major manufacturers like Pfizer-BioNTech and Moderna have adapted their production strategies to meet this sustained demand, with both companies releasing variant-specific boosters targeting the latest strains.

Growing evidence supporting the effectiveness of booster doses in preventing severe illness has strengthened their market position. According to the UK Health Security Agency, booster shots provided 88% additional protection against hospitalization from the Omicron variant in studies conducted through 2023. In March 2024, Moderna announced positive trial results for its combination respiratory booster vaccine, which targets both Covid-19 variants and influenza strains, potentially revolutionizing the seasonal vaccination approach.

Country/Region-wise Acumens

Will Advanced Cold Chain Logistics in North America Drive Covid-19 Vaccine Market Growth?

North America maintains its leadership position in the global Covid-19 vaccine market through robust healthcare infrastructure and substantial government investments in vaccination programs. According to the US CDC, more than 674 million Covid-19 vaccine doses were administered in the United States by December 2023, demonstrating the region's massive vaccine uptake. The presence of major pharmaceutical companies and research institutions has further strengthened North America's market dominance, with recent expansions of manufacturing facilities by Pfizer in Michigan and Moderna in Massachusetts announced in early 2024.

Advanced cold chain logistics and efficient distribution networks have enabled seamless vaccine delivery across the continent, supporting market growth. Health Canada reported that approximately 83% of eligible Canadians completed their primary vaccination series by the end of 2023. Moderna's announcement in March 2024 regarding the establishment of a new research and development hub in Toronto, focusing on next-generation mRNA technologies, reinforces North America's position as a key innovation center for vaccine development.

Will Robust Healthcare Infrastructure Enhance Adoption of Covid-19 Vaccine in Asia Pacific?

North America maintains its leadership position in the global Covid-19 vaccine market through robust healthcare infrastructure and substantial government investments in vaccination programs. According to the US CDC, more than 674 million Covid-19 vaccine doses were administered in the United States by December 2023, demonstrating the region's massive vaccine uptake. The presence of major pharmaceutical companies and research institutions has further strengthened North America's market dominance, with recent expansions of manufacturing facilities by Pfizer in Michigan and Moderna in Massachusetts announced in early 2024.

Advanced cold chain logistics and efficient distribution networks have enabled seamless vaccine delivery across the continent, supporting market growth. Health Canada reported that approximately 83% of eligible Canadians completed their primary vaccination series by the end of 2023. Moderna's announcement in March 2024 regarding the establishment of a new research and development hub in Toronto, focusing on next-generation mRNA technologies, reinforces North America's position as a key innovation center for vaccine development.

Competitive Landscape

The Covid-19 vaccine market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the Covid-19 vaccine market include:

• Pfizer-BioNTech
• Moderna
• AstraZeneca
• Johnson & Johnson (Janssen)
• Novavax
• Sinovac Biotech
• Sinopharm
• Sputnik V (Gamaleya Research Institute)
• Bharat Biotech
• COVAXIN (Bharat Biotech)
• CanSino Biologics
• Zydus Cadila
• Valneva
• Merck & Co.
• Sanofi
• GSK (GlaxoSmithKline)
• CureVac
• Vaxart
• ModernaTX
• Inovio Pharmaceuticals

Latest Developments

• In October 2023, several pharmaceutical companies announced the results of clinical trials for new Covid-19 vaccines aimed at emerging variants, demonstrating increased efficacy and safety profiles.
• In September 2023, the WHO approved a new vaccine platform designed for rapid development and deployment in response to future Covid-19 variants, enhancing global readiness.

Covid-19 Vaccine Market, By Category

• Technology:
• mRNA Technology
• Viral Vector Technology
• Protein Subunit Technology
• DNA Technology
• Application:
• Primary Vaccination
• Booster Doses
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Covid-19 Vaccine Market, By Technology

• mRNA vaccines
• Viral Vector Vaccines
• DNA vaccines
• Protein Subunit Vaccines
• Inactivated Vaccines

5. Covid-19 Vaccine Market, By Application

• Primary Vaccination
• Booster doses: Given

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Pfizer
• Moderna
• AstraZeneca
• Johnson & Johnson
• Sinopharm
• Sinovac Biotech
• Bharat Biotech

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References